2588-0519

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice

Publishing House OKI

View prefix report (10.37489)

Health Score

0 Excellent

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 20 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact20 DOIs
2

Attach ORCID iDs across 12 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact12 DOIs
3

Deposit reference lists for 2 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact2 DOIs

DOIs for this ISSN

Showing the top 5 of 248 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Use of unlicensed drugs and off-label drug use: focus on COV… (10.37489/2588-0519-2020-s4-120-129)
Abstract
22.58 7
2 Socio-economic burden of COVID-19 in the Russian Federation (10.37489/2588-0519-2020-1-35-44)
Abstract
21.13 6
3 Lifestyle Changes in Medical Students during the COVID-19 Pa… (10.37489/2588-0519-2022-1-64-71)
Abstract
21.13 6
4 Specifics of motivation of volunteers participating in in a… (10.37489/2588-0519-2022-4-4-12)
Abstract
17.47 4
5 Clinical Pharmacology in Health Care, Teaching and Research (10.37489/2588-0519-2020-s2)
References ORCID
15.05 1
6 A social-economic burden of rhinosinusitis with nasal polyps… (10.37489/2588-0519-2021-3-16-30)
ORCID
15.05 3
7 Analysis of the effectiveness of the use of financial resour… (10.37489/2588-0519-2021-4-75-79)
References ORCID
15.05 1
8 Health-economic analysis of tocilizumab in patients with rhe… (10.37489/2588-0519-2020-1-23-33)
Abstract
11.93 2
9 Current aspects of risk management in clinical trials (10.37489/2588-0519-2020-1-45-52)
ORCID
11.93 2
10 Resource consumption and patient employability during system… (10.37489/2588-0519-2021-1-46-54)
ORCID
11.93 2
11 Factors, influencing to the recruitment of international mul… (10.37489/2588-0519-2022-4-13-23)
Abstract
11.93 2
12 Optimization of laboratory support costs in a multidisciplin… (10.37489/2588-0519-2022-4-24-37)
Abstract
11.93 2
13 Comparative pharmacoeconomic analysis of the use of apixaban… (10.37489/2588-0519-2022-4-50-59)
Abstract
11.93 2
14 Review of the European standard for postgraduate training of… (10.37489/2588-0519-2020-1-100-111)
Abstract
7.53 1
15 Pharmacoeconomic evaluation of apixaban use for the treatmen… (10.37489/2588-0519-2022-4-38-49)
Abstract
7.53 1
16 Palliative care for patients with primary and metastatic bra… (10.37489/2588-0519-2025-3-127-136)
ORCID
7.53 1
17 Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxe… (10.37489/2588-0519-2020-1-4-21)
0.00 2
18 Analysis of the drug prescription for obese patients in Mosc… (10.37489/2588-0519-2020-1-53-60)
Abstract
0.00 0
19 Risks associated with the ethical aspects of conducting clin… (10.37489/2588-0519-2020-1-61-68)
0.00 5
20 Oral anticoagulants in the prevention of thromboembolic comp… (10.37489/2588-0519-2020-1-69-79)
0.00 5
21 The ability to predict the results of bioequivalence studies… (10.37489/2588-0519-2020-1-80-99)
Abstract
0.00 0
22 Influence of dupilumab on the economic burden of severe asth… (10.37489/2588-0519-2020-3-15-26)
0.00 9
23 Economic consequences of mandatory price re-registration for… (10.37489/2588-0519-2020-3-27-33)
0.00 2
24 Analysis of the long-term effectiveness of a drug in the tre… (10.37489/2588-0519-2020-3-35-39)
0.00 1
25 Pharmacoeconomic comparison of insulin glargine and insulin… (10.37489/2588-0519-2020-3-4-14)
0.00 1
26 harmacoeconomic feasibility of using the drug upadacitinib i… (10.37489/2588-0519-2020-3-40-51)
0.00 0
27 Pragmatic clinical trials (10.37489/2588-0519-2020-3-52-60)
0.00 5
28 Drug-induced liver damage with cholestasis (10.37489/2588-0519-2020-3-61-74)
0.00 4
29 Implementation of the concept of standard operating procedur… (10.37489/2588-0519-2020-3-75-84)
0.00 3
30 The pharmacoepidemiology of potential drug-drug interactions… (10.37489/2588-0519-2020-3-85-92)
0.00 0
31 The value of information service for the rational use of noo… (10.37489/2588-0519-2020-3-93-103)
0.00 0
32 Th e clinical-economic analysis of Dupilumab in severe asthm… (10.37489/2588-0519-2020-5-15-26)
0.00 1
33 Clinical-economic evaluation of a screening for Pompe diseas… (10.37489/2588-0519-2020-5-27-37)
0.00 0
34 Cystic fibrosis as a social-economic burden (10.37489/2588-0519-2020-5-38-49)
0.00 2
35 The pharmacoeconomic comparison of the fixed insulin glargin… (10.37489/2588-0519-2020-5-4-14)
0.00 3
36 Pharmacoeconomic evaluation of ipragliflozin in combination… (10.37489/2588-0519-2020-5-50-63)
0.00 0
37 Legal aspects of conducting real-world studies (10.37489/2588-0519-2020-5-64-69)
0.00 3
38 Polymorphism of genes of arterial hypertension among childre… (10.37489/2588-0519-2020-5-70-79)
0.00 0
39 Palliative care organization in the light of updated legisla… (10.37489/2588-0519-2020-5-80-86)
ORCID
0.00 0
40 Rationale for use mefloquine for COVID-19 treatment (10.37489/2588-0519-2020-s4-103-105)
0.00 0
41 Current and future use of favipiravir in patients with COVID… (10.37489/2588-0519-2020-s4-106-114)
0.00 4
42 Possibility to use barycytinib in patients with COVID-19, in… (10.37489/2588-0519-2020-s4-11-14)
0.00 2
43 Monitoring of safety using favipiravir: risk management of a… (10.37489/2588-0519-2020-s4-115-119)
0.00 5
44 Is it possible to use riamilovir to prevent infection and tr… (10.37489/2588-0519-2020-s4-15-17)
0.00 4
45 Possibility to use direct oral anticoagulants to prevent thr… (10.37489/2588-0519-2020-s4-18-22)
0.00 3
46 Methylprednisolone in acute respiratory distress-syndrome in… (10.37489/2588-0519-2020-s4-23-27)
0.00 1
47 Current and future use of angiotensin II receptor blockers i… (10.37489/2588-0519-2020-s4-28-31)
0.00 0
48 Can inhalations of hyaluronidase be used in acute respirator… (10.37489/2588-0519-2020-s4-32-34)
0.00 0
49 Possibilities for the use of tofacitinib in patients with CO… (10.37489/2588-0519-2020-s4-35-38)
0.00 0
50 Use of etiotropic and pathogenetic medicines for COVID-19 in… (10.37489/2588-0519-2020-s4-39-46)
0.00 0